시장보고서
상품코드
1180179

세계의 진통제 시장 : 종류별(비오피오이드, 오피오이드), 투여 경로별(경구, 정맥내, 직장, 경피, 국소)-기회 분석과 업계 예측(2022-2030년)

Analgesics Market by Type (Non-opioids and Opioids) and by Route of Administration (Oral, Intravenous, Rectal, Transdermal, and Topical) - Global Opportunity Analysis and Industry Forecast 2022-2030

발행일: | 리서치사: Next Move Strategy Consulting | 페이지 정보: 영문 173 Pages | 배송안내 : 1-2일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 진통제 시장 규모는 2021년 3,503만 달러에서 2030년에는 5,686만 달러에 달하고, 2022-2030년 예측기간 중 CAGR로 4.9%의 성장이 예측됩니다. 급성·만성질환 증가, 고령자 인구 증가는 시장 성장을 촉진하고 있습니다. 그러나 약물남용, 염증성 통증 치료의 생물제제 사용 증가, 엄격한 규제 정책은 시장 성장을 저해하고 있습니다.

세계의 진통제(Analgesics) 시장에 대해 조사했으며, 시장 개요, 시장 분석, 기업 개요 등의 정보를 제공하고 있습니다.

목차

제1장 서론

제2장 진통제 시장 - 주요 요약

  • 시장 현황(100만 달러)(2021-2030년)

제3장 시장 개요

  • 시장 정의와 범위
  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 기회

제4장 세계의 진통제 시장 : 종류별

  • 개요
  • 비오피오이드
    • 비오피오이드 시장 : 지역별
  • 오피오이드
    • 오피오이드 시장 : 지역별

제5장 세계의 진통제 시장 : 투여 경로별

  • 개요
  • 경구
    • 경구 시장 : 지역별
  • 정맥내
    • 정맥내 시장 : 지역별
  • 직장
    • 직장 시장 : 지역별
  • 경피
    • 경피 시장 : 지역별
  • 국소
    • 국소 시장 : 지역별

제6장 세계의 진통제 : 지역별

  • 개요
  • 북미
  • 유럽
  • 아시아태평양
  • 기타 지역

제7장 기업 개요

  • ABBOTT LABORATORIES
  • BAYER AG
  • GLAXOSMITHKLINE PLC
  • JOHNSON & JOHNSON
  • NOVARTIS AG
  • PFIZER INC
  • SANOFI SA
  • TEVA PHARMACEUTICALS
  • ABBVIE INC
  • SUN PHARMA
KSM 23.01.20

The analgesics market size was valued at USD 35.03 million in 2021 and is expected to reach USD 56.86 million by 2030, at a CAGR of 4.9% during 2022-2030.

The increasing number of various acute and chronic diseases such as cancer, arthritis, and cardiovascular diseases is one of the major factors driving the growth of the analgesics market. According to Globocan 2020 report, published by International Agency for Research on Cancer (IARC), cancer cases across the globe has risen to 19.3 million, which drives the growth of the analgesics market. In addition, growing geriatric population has also increased the demand for analgesics drugs.

However, factors such as drug abuse, growing use of biologics for the treatment of inflammatory pain, and stringent regulatory policies are hampering the market growth to some extent. On the contrary, increasing demand for personalized medicine and development of new pain-relieving drugs are expected to create significant growth opportunities for the market players.

Segment Overview

The analgesics industry has been segmented based on type, route of administration, and geography.

  • On the basis of type, the market is categorized into opioids and non-opioids.
  • On the basis of route of administration, the market is classified into oral, intravenous, rectal, transdermal, and topical.
  • Region-wise, the market is classified into North America, Europe, Asia-Pacific, and RoW.

Regional Analysis

The North America market is projected to hold the dominant share by 2030

North America holds the lion's share of the global analgesics market share at present and is expected to continue its dominance during the forecast period. This can be attributed to factors such as growing burden of pain management and rising adoption of opioids. In addition, factors such as increasing prevalence of cancer, surging number of surgeries, and rising research and development (R&D) activities in the pharmaceutical sector are also expected to drive the over-the-counter analgesics market growth in this region.

Key Market Players

The emerging and efficient key players in the analgesics market include the following:

  • Abbott Laboratories
  • Bayer AG
  • Glaxosmithkline plc
  • Johnson and Johnson
  • Pfizer, Inc
  • Novartis AG
  • Teva Pharmaceuticals
  • Sanofi SA
  • ABBVIE INC
  • Sun Pharmaceutical Industries, Inc.

Recent Developments

June 2022

AbbVie announced that FDA has approved Skyrizi (risankizumab-rzaa) as the first interleukin-23 (IL-23) inhibitor to treat adults with moderately to severely active Crohn's disease (CD).

May 2022

Pfizer Inc. acquired Biohaven Pharmaceutical Holding Company Ltd. This acquisition was done for production of NURTEC ODT for acute treatment and episodic prevention of migraine in adults.

November 2021

Sun Pharma launched Molnupiravir. Molnupiravir 200mg Capsule was to treat adults with COVID-19 who do not require supplemental oxygen and who are at increased risk of developing severe COVID-19.

September 2021

Novartis announced that the US Food and Drug Administration (FDA) had granted fast-track designation for LNA043 for the treatment of osteoarthritis of the knee. LNA043 was developed as a potential first in class disease modifying treatment for osteoarthritis (OA).

January 2021

Abbott launched the NeuroSphere myPath digital health app designed to track and report pain relief in chronic pain patients with physicians prior to device implant.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. WHO SHOULD READ THIS REPORT
  • 1.3. KEY MARKET SEGMENTS
  • 1.4. RESEARCH METHODOLOGY
    • 1.4.1 SECONDARY RESEARCH
    • 1.4.2 DATA ANALYSIS FRAMEWORK
    • 1.4.3 MARKET SIZE ESTIMATION
    • 1.4.4 FORECASTING
    • 1.4.5 PRIMARY RESEARCH AND DATA VALIDATION

2. ANALGESICS MARKET - EXECUTIVE SUMMARY

  • 2.1. MARKET SNAPSHOT, 2021 - 2030, MILLION USD

3. MARKET OVERVIEW

  • 3.1. MARKET DEFINITION AND SCOPE
  • 3.2. MARKET DYNAMICS
    • 3.2.1 DRIVERS
      • 3.2.1.1. INCREASING CHRONIC AND INFECTIOUS DISEASES AMONG PEOPLE
      • 3.2.1.2. INCREASING NUMBER OF MEDICAL SURGERIES ACROSS THE WORLD
      • 3.2.1.3. ELEVATING AWARENESS ABOUT PALLIATIVE CARE AND PAIN MANAGEMENT
    • 3.2.2 RESTRAINTS
      • 3.2.2.1. CHANGING REGULATORY LANDSCAPE IN THE MEDICAL DRUGS INDUSTRY
    • 3.2.3 OPPORTUNITIES
      • 3.2.3.1. INCREASING NUMBER OF STRATEGIC COLLABORATIONS AND ADVANCEMENTS IN MEDICAL DRUG DEVELOPMENT

4. GLOBAL ANALGESICS MARKET, BY TYPE

  • 4.1. OVERVIEW
  • 4.2. NON-OPIOID
    • 4.2.1 NON-OPIOID MARKET, BY REGION
  • 4.3. OPIOIDS
    • 4.3.1 OPIOIDS MARKET, BY REGION

5. GLOBAL ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION

  • 5.1. OVERVIEW
  • 5.2. ORAL ROUTE
    • 5.2.1 ORAL ROUTE MARKET, BY REGION
  • 5.3. INTRAVENOUS ROUTE
    • 5.3.1 INTRAVENOUS ROUTE MARKET, BY REGION
  • 5.4. RECTAL ROUTE
    • 5.4.1 RECTAL ROUTE MARKET, BY REGION
  • 5.5. TRANSDERMAL ROUTE
    • 5.5.1 TRANSDERMAL ROUTE MARKET, BY REGION
  • 5.6. TOPICAL ROUTE
    • 5.6.1 TOPICAL ROUTE MARKET, BY REGION

6. GLOBAL ANALGESICS BY REGION

  • 6.1. OVERVIEW
  • 6.2. NORTH AMERICA
    • 6.2.1 NORTH AMERICA ANALGESICS MARKET, BY TYPE
    • 6.2.2 NORTH AMERICA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION
    • 6.2.3 NORTH AMERICA ANALGESICS, BY COUNTRY
      • 6.2.3.1. U.S.
        • 6.2.3.1.1. U.S. Analgesics Market, By Type
        • 6.2.3.1.2. U.S. Analgesics Market, By Route of Administration
      • 6.2.3.2. Canada
        • 6.2.3.2.1. Canada Analgesics Market, By Type
        • 6.2.3.2.2. Canada Analgesics Market, By Route of Administration
      • 6.2.3.3. Mexico
        • 6.2.3.3.1. Mexico Analgesics Market, By Type
        • 6.2.3.3.2. Mexico Analgesics Market, By Route of Administration
  • 6.3. EUROPE
    • 6.3.1 EUROPE ANALGESICS MARKET, BY TYPE
    • 6.3.2 EUROPE ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION
    • 6.3.3 EUROPE ANALGESICS, BY COUNTRY
      • 6.3.3.1. UK
        • 6.3.3.1.1. UK Analgesics Market, By Type
        • 6.3.3.1.2. UK Analgesics Market, By Route of Administration
      • 6.3.3.2. Germany
        • 6.3.3.2.1. Germany Analgesics Market, By Type
        • 6.3.3.2.2. Germany Analgesics Market, By Route of Administration
      • 6.3.3.3. Spain
        • 6.3.3.3.1. Spain Analgesics Market, By Type
        • 6.3.3.3.2. Spain Analgesics Market, By Route of Administration
      • 6.3.3.4. Sweden
        • 6.3.3.4.1. Sweden Analgesics Market, By Type
        • 6.3.3.4.2. Sweden Analgesics Market, By Route of Administration
      • 6.3.3.5. France
        • 6.3.3.5.1. France Analgesics Market, By Type
        • 6.3.3.5.2. France Analgesics Market, By Route of Administration
      • 6.3.3.6. Russia
        • 6.3.3.6.1. Russia Analgesics Market, By Type
        • 6.3.3.6.2. Russia Analgesics Market, By Route of Administration
      • 6.3.3.7. Denmark
        • 6.3.3.7.1. Denmark Analgesics Market, By Type
        • 6.3.3.7.2. Denmark Analgesics Market, By Route of Administration
      • 6.3.3.8. Rest of Europe
        • 6.3.3.8.1. Rest of Europe Analgesics Market, By Type
        • 6.3.3.8.2. Rest of Europe Analgesics Market, By Route of Administration
  • 6.4. ASIA-PACIFIC
    • 6.4.1 ASIA-PACIFIC ANALGESICS MARKET, BY TYPE
    • 6.4.2 ASIA-PACIFIC ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION
    • 6.4.3 ASIA-PACIFIC ANALGESICS, BY COUNTRY
      • 6.4.3.1. Japan
        • 6.4.3.1.1. Japan Analgesics Market, By Type
        • 6.4.3.1.2. Japan Analgesics Market, By Route of Administration
      • 6.4.3.2. China
        • 6.4.3.2.1. China Analgesics Market, By Type
        • 6.4.3.2.2. China Analgesics Market, By Route of Administration
      • 6.4.3.3. India
        • 6.4.3.3.1. India Analgesics Market, By Type
        • 6.4.3.3.2. India Analgesics Market, By Route of Administration
      • 6.4.3.4. Australia
        • 6.4.3.4.1. Australia Analgesics Market, By Type
        • 6.4.3.4.2. Australia Analgesics Market, By Route of Administration
      • 6.4.3.5. Indonesia
        • 6.4.3.5.1. Indonesia Analgesics Market, By Type
        • 6.4.3.5.2. Indonesia Analgesics Market, By Route of Administration
      • 6.4.3.6. Rest of Asia-Pacific
        • 6.4.3.6.1. Rest of Asia-Pacific Analgesics Market, By Type
        • 6.4.3.6.2. Rest of Asia-Pacific Analgesics Market, By Route of Administration
  • 6.5. REST OF WORLD
    • 6.5.1 REST OF WORLD ANALGESICS MARKET, BY TYPE
    • 6.5.2 REST OF WORLD ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION
    • 6.5.3 REST OF WORLD ANALGESICS, BY COUNTRY
      • 6.5.3.1. Brazil
        • 6.5.3.1.1. Brazil Analgesics Market, By Type
        • 6.5.3.1.2. Brazil Analgesics Market, By Route of Administration
      • 6.5.3.2. Venezuela
        • 6.5.3.2.1. Venezuela Analgesics Market, By Type
        • 6.5.3.2.2. Venezuela Analgesics Market, By Route of Administration
      • 6.5.3.3. Chile
        • 6.5.3.3.1. Chile Analgesics Market, By Type
        • 6.5.3.3.2. Chile Analgesics Market, By Route of Administration
      • 6.5.3.4. Kingdom of Saudi Arabia (KSA)
        • 6.5.3.4.1. Kingdom of Saudi Arabia (KSA) Analgesics Market, By Type
        • 6.5.3.4.2. Kingdom of Saudi Arabia (KSA) Analgesics Market, By Route of Administration
      • 6.5.3.5. UAE
        • 6.5.3.5.1. UAE Analgesics Market, By Type
        • 6.5.3.5.2. UAE Analgesics Market, By Route of Administration
      • 6.5.3.6. Morocco
        • 6.5.3.6.1. Morocco Analgesics Market, By Type
        • 6.5.3.6.2. Morocco Analgesics Market, By Route of Administration
      • 6.5.3.7. Kenya
        • 6.5.3.7.1. Kenya Analgesics Market, By Type
        • 6.5.3.7.2. Kenya Analgesics Market, By Route of Administration
      • 6.5.3.8. Nigeria
        • 6.5.3.8.1. Nigeria Analgesics Market, By Type
        • 6.5.3.8.2. Nigeria Analgesics Market, By Route of Administration
      • 6.5.3.9. Remaining Countries
        • 6.5.3.9.1. Remaining Countries Analgesics Market, By Type
        • 6.5.3.9.2. Remaining Countries Analgesics Market, By Route of Administration

7. COMPANY PROFILES

  • 7.1. ABBOTT LABORATORIES
    • 7.1.1 COMPANY OVERVIEW
    • 7.1.2 COMPANY SNAPSHOT
    • 7.1.3 OPERATING BUSINESS SEGMENTS
    • 7.1.4 PRODUCT PORTFOLIO
    • 7.1.5 BUSINESS PERFORMANCE
    • 7.1.6 SALES BY BUSINESS SEGMENT
    • 7.1.7 SALES BY GEOGRAPHIC SEGMENT
    • 7.1.8 KEY STRATEGIC MOVES & DEVELOPMENTS
    • 7.1.9 PRIMARY MARKET COMPETITORS
  • 7.2. BAYER AG
    • 7.2.1 COMPANY OVERVIEW
    • 7.2.2 COMPANY SNAPSHOT
    • 7.2.3 OPERATING BUSINESS SEGMENTS
    • 7.2.4 PRODUCT PORTFOLIO
    • 7.2.5 BUSINESS PERFORMANCE
    • 7.2.6 SALES BY BUSINESS SEGMENT
    • 7.2.7 SALES BY GEOGRAPHIC SEGMENT
    • 7.2.8 KEY STRATEGIC MOVES & DEVELOPMENTS
    • 7.2.9 PRIMARY MARKET COMPETITORS
  • 7.3. GLAXOSMITHKLINE PLC
    • 7.3.1 COMPANY OVERVIEW
    • 7.3.2 COMPANY SNAPSHOT
    • 7.3.3 OPERATING BUSINESS SEGMENTS
    • 7.3.4 PRODUCT PORTFOLIO
    • 7.3.5 BUSINESS PERFORMANCE
    • 7.3.6 SALES BY BUSINESS SEGMENT
    • 7.3.7 SALES BY GEOGRAPHIC SEGMENT
    • 7.3.8 KEY STRATEGIC MOVES & DEVELOPMENTS
    • 7.3.9 PRIMARY MARKET COMPETITORS
  • 7.4. JOHNSON & JOHNSON
    • 7.4.1 COMPANY OVERVIEW
    • 7.4.2 COMPANY SNAPSHOT
    • 7.4.3 OPERATING BUSINESS SEGMENTS
    • 7.4.4 PRODUCT PORTFOLIO
    • 7.4.5 BUSINESS PERFORMANCE
    • 7.4.6 SALES BY BUSINESS SEGMENT
    • 7.4.7 SALES BY GEOGRAPHIC SEGMENT
    • 7.4.8 KEY STRATEGIC MOVES & DEVELOPMENTS
    • 7.4.9 PRIMARY MARKET COMPETITORS
  • 7.5. NOVARTIS AG
    • 7.5.1 COMPANY OVERVIEW
    • 7.5.2 COMPANY SNAPSHOT
    • 7.5.3 OPERATING BUSINESS SEGMENTS
    • 7.5.4 PRODUCT PORTFOLIO
    • 7.5.5 BUSINESS PERFORMANCE
    • 7.5.6 SALES BY BUSINESS SEGMENT
    • 7.5.7 SALES BY GEOGRAPHIC SEGMENT
    • 7.5.8 KEY STRATEGIC MOVES & DEVELOPMENTS
    • 7.5.9 PRIMARY MARKET COMPETITORS
  • 7.6. PFIZER INC
    • 7.6.1 COMPANY OVERVIEW
    • 7.6.2 COMPANY SNAPSHOT
    • 7.6.3 OPERATING BUSINESS SEGMENTS
    • 7.6.4 PRODUCT PORTFOLIO
    • 7.6.5 BUSINESS PERFORMANCE
    • 7.6.6 SALES BY GEOGRAPHIC SEGMENT
    • 7.6.7 SALES BY GEOGRAPHIC SEGMENT
    • 7.6.8 KEY STRATEGIC MOVES & DEVELOPMENTS
    • 7.6.9 PRIMARY MARKET COMPETITORS
  • 7.7. SANOFI SA
    • 7.7.1 COMPANY OVERVIEW
    • 7.7.2 COMPANY SNAPSHOT
    • 7.7.3 OPERATING BUSINESS SEGMENTS
    • 7.7.4 PRODUCT PORTFOLIO
    • 7.7.5 BUSINESS PERFORMANCE
    • 7.7.6 SALES BY BUSINESS SEGMENT
    • 7.7.7 SALES BY GEOGRAPHIC SEGMENT
    • 7.7.8 KEY STRATEGIC MOVES & DEVELOPMENTS
    • 7.7.9 PRIMARY MARKET COMPETITORS
  • 7.8. TEVA PHARMACEUTICALS
    • 7.8.1 COMPANY OVERVIEW
    • 7.8.2 COMPANY SNAPSHOT
    • 7.8.3 PRODUCT PORTFOLIO
    • 7.8.4 BUSINESS PERFORMANCE
    • 7.8.5 SALES BY GEOGRAPHIC SEGMENT
    • 7.8.6 KEY STRATEGIC MOVES & DEVELOPMENTS
    • 7.8.7 PRIMARY MARKET COMPETITORS
  • 7.9. ABBVIE INC
    • 7.9.1 COMPANY OVERVIEW
    • 7.9.2 COMPANY SNAPSHOT
    • 7.9.3 OPERATING BUSINESS SEGMENTS
    • 7.9.4 PRODUCT PORTFOLIO
    • 7.9.5 BUSINESS PERFORMANCE
    • 7.9.6 SALES BY BUSINESS SEGMENT
    • 7.9.7 SALES BY GEOGRAPHIC SEGMENT
    • 7.9.8 KEY STRATEGIC MOVES & DEVELOPMENTS
    • 7.9.9 PRIMARY MARKET COMPETITORS
  • 7.10. SUN PHARMA
    • 7.10.1 COMPANY OVERVIEW
    • 7.10.2 COMPANY SNAPSHOT
    • 7.10.3 PRODUCT PORTFOLIO
    • 7.10.4 BUSINESS PERFORMANCE
    • 7.10.5 SALES BY GEOGRAPHIC SEGMENT
    • 7.10.6 KEY STRATEGIC MOVES & DEVELOPMENTS
    • 7.10.7 PRIMARY MARKET COMPETITORS
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제